Hims & Hers Health Inc.’s stock fell sharply on Monday after pharmaceutical giant Novo Nordisk, maker of the weight-loss drug ...

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” under the ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Novo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Novo Nordisk announced it will stop collaborating with Hims & Hers Health regarding the distribution of Wegovy weight loss ...

Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs.

The FDA had resolved the shortage of Wegovy in April, and telehealth providers were advised to stop selling compounded ...

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health ...

Shares in Novo Nordisk fell as much as 3.5% on Monday after detailed trial data on its experimental obesity drug CagriSema ...